British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the U.S. by 2030, the company announced on Monday.
“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” AstraZeneca CEO Pascal Soriot said in a statement. “I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly-skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
AstraZeneca also announced last November $3.5 billion of capital investment in the country, focused on R&D and manufacturing. The company said it included $2 billion of new investment that would create more than 1,000 new, high-skilled jobs in the U.S. 
ELI LILLY INVESTING $27B MORE IN US MANUFACTURING
Part of the investment included a $300 million cell therapy manufacturing plant located in Maryland that opened in May. Once in operation, the site will use a relatively new cancer treatment called CAR-T cell therapy to help treat blood cancers like lymphoma and leukemia.
The U.S. is AstraZeneca’s largest market and represents 42% of the company’s total revenue. The pharma giant’s goal is to increase that figure to 50% by 2030.
WHO’S INVESTING IN AMERICA? 23 BIG COMPANIES THAT JUST PROMISED BILLIONS UNDER TRUMP
AstraZeneca employs 18,000 people and supports 92,000 jobs overall in the U.S. It also currently has 19 R&D, manufacturing and commercial sites in the country.
The company said it contributed $5 billion directly to the nation’s economy and created about $20 billion worth of overall value for the U.S. economy.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Monday’s announcement marks the latest investment in America under the Trump administration.
Other drugmakers, including Bristol Myers Squibb, Roche, Eli Lilly and Johnson & Johnson, previously announced intentions to invest billions in the U.S. for R&D, manufacturing and factory expansions.
